William P. Fay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William P. Fay has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Andrew C. Parker
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor 48109-0644, USA
4 shared publicationsYanhong Zhu
From the Department of Internal Medicine, University of Michigan Medical School, Ann Arbor
3 shared publications- Peter Carmeliet
Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium
2 shared publications Peter M. Farrehi
From the Department of Internal Medicine, University of Michigan Medical School, Ann Arbor
2 shared publicationsA C Parker
1 shared publicationAlvin H. Schmaier
From the Department of Internal Medicine, University of Michigan Medical School, Ann Arbor
1 shared publication
Latest Publications
- 7 December 2004
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (23) , 3594-3598
Factor V Leiden Inhibits Fibrinolysis In Vivo
Background— Factor V Leiden (fV Leiden ) predisposes to thrombosis by enhancing thrombin formation. This study tested the hypothesis that fV Leiden inhibits fibrinolysis in vivo. Methods and Results— Radiolabeled clots were injected into the jugular veins of wild-type mice and mice heterozygous ( fV +/Q ) or homozygous ( fV Q/Q ) for fV Leiden . Mean percent clot lysis 5 hours later was significantly reduced in fV Q/Q mice (14.3±3.6%, n=13) compared with wild-type mice (40.2±7.0%, n=17; P fV +/Q mice (29.4±8.7%, n=9; P fV Q/Q , P =0.36 versus wild type). The rate of in vitro lysis of plasma clots prepared from fV +/Q or fV Q/Q mice was significantly slower than that of wild-type plasma clots, whereas in vitro clot lysis did not differ significantly between groups after inhibiting thrombin-activatable fibrinolysis inhibitor. Conclusions— fV Leiden inhibits fibrinolysis in vivo, suggesting an additional pathway by which this mutation promotes thrombosis.
- 7 December 2004
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (23) , 3594-3598
Factor V Leiden Inhibits Fibrinolysis In Vivo
Background— Factor V Leiden (fV Leiden ) predisposes to thrombosis by enhancing thrombin formation. This study tested the hypothesis that fV Leiden inhibits fibrinolysis in vivo. Methods and Results— Radiolabeled clots were injected into the jugular veins of wild-type mice and mice heterozygous ( fV +/Q ) or homozygous ( fV Q/Q ) for fV Leiden . Mean percent clot lysis 5 hours later was significantly reduced in fV Q/Q mice (14.3±3.6%, n=13) compared with wild-type mice (40.2±7.0%, n=17; P fV +/Q mice (29.4±8.7%, n=9; P fV Q/Q , P =0.36 versus wild type). The rate of in vitro lysis of plasma clots prepared from fV +/Q or fV Q/Q mice was significantly slower than that of wild-type plasma clots, whereas in vitro clot lysis did not differ significantly between groups after inhibiting thrombin-activatable fibrinolysis inhibitor. Conclusions— fV Leiden inhibits fibrinolysis in vivo, suggesting an additional pathway by which this mutation promotes thrombosis.
- 1 September 2004
- Vol. 92 (3) , 486-94
Murine thrombosis models.
Due to exciting advances in molecular biology, the laboratory mouse has become an important and frequently used model for studying thrombosis. This article reviews several experimental approaches that have been used to study arterial, venous, and microvascular thrombosis in mice. The advantages and limitations of different models are examined. Related topics of mouse anesthesia, phlebotomy, and in vitro hemostasis testing are also reviewed.
- 1 September 2004
- Vol. 92 (3) , 486-94
Murine thrombosis models.
Due to exciting advances in molecular biology, the laboratory mouse has become an important and frequently used model for studying thrombosis. This article reviews several experimental approaches that have been used to study arterial, venous, and microvascular thrombosis in mice. The advantages and limitations of different models are examined. Related topics of mouse anesthesia, phlebotomy, and in vitro hemostasis testing are also reviewed.
- 1 July 2004
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 14 (5) , 196-202
Plasminogen Activator Inhibitor 1, Fibrin, and the Vascular Response to Injury
- 1 July 2004
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 14 (5) , 196-202
Plasminogen Activator Inhibitor 1, Fibrin, and the Vascular Response to Injury
- 1 January 2004
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 92 (09) , 486-494
Murine thrombosis models
Summary: Due to exciting advances in molecular biology, the laboratory mouse has become an important and frequently used model for studying thrombosis. This article reviews several experimental approaches that have been used to study arterial, venous, and microvascular thrombosis in mice. The advantages and limitations of different models are examined. Related topics of mouse anesthesia, phlebotomy, and in vitro hemostasis testing are also reviewed.
- 1 January 2004
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 92 (09) , 486-494
Murine thrombosis models
Summary: Due to exciting advances in molecular biology, the laboratory mouse has become an important and frequently used model for studying thrombosis. This article reviews several experimental approaches that have been used to study arterial, venous, and microvascular thrombosis in mice. The advantages and limitations of different models are examined. Related topics of mouse anesthesia, phlebotomy, and in vitro hemostasis testing are also reviewed.
- Open Access
- 15 August 2003
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 188 (4) , 497-505
Plasminogen Enhances Virulence of Group A Streptococci by Streptokinase‐Dependent and Streptokinase‐Independent Mechanisms
Interactions between host plasminogen (Plg) and streptokinase (SK) secreted by group A streptococci (GAS) have been hypothesized to promote bacterial
- 15 August 2003
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 188 (4) , 497-505
Open AccessPlasminogen Enhances Virulence of Group A Streptococci by Streptokinase‐Dependent and Streptokinase‐Independent Mechanisms
Interactions between host plasminogen (Plg) and streptokinase (SK) secreted by group A streptococci (GAS) have been hypothesized to promote bacterial
- 1 July 2002
- Published by Wiley in Clinical Cardiology
- Vol. 25 (7) , 346-349
Prolonged low‐dose thrombolytic therapy: A novel adjunctive strategy in the management of an infected right atrial thrombus
An 81‐year‐old man presented with a large, infected right atrial thrombus that was refractory to anticoagulants and several courses of antibiotics. The risk of surgical removal of the thrombus, which was associated with a pacemaker electrode, was considered prohibitive. The patient was treated for 7 days with low‐dose (40 mg/day) tissue‐type plasminogen activator (t‐PA). Hemostatic monitoring during infusion revealed (1) aplasma t‐PA antigen that was approximately 5% of that achieved during short‐course t‐PA for acute myocardial infarction, (2) biochemical evidence of prolonged clot lysis, and (3) no significant depletion of fibrinogen or plas‐minogen. Nearly complete dissolution of the thrombus was observed. His bacteremia was eradicated by intravenous penicillin despite the presence of the pacemaker lead. This case highlights the benefits of combined antibiotic and thrombolytic therapy and documents for the first time the response of the human hemostatic system to prolonged t‐PA infusion and the plasma t‐PA levels attained when thrombolytic therapy is administered in this manner. Prolonged courses of fibrinolytic agents may be a good alternative to surgical intervention in selected patients with infected, right‐sided intracardiac thrombi.
- 1 July 2002
- Published by Wiley in Clinical Cardiology
- Vol. 25 (7) , 346-349
Prolonged low‐dose thrombolytic therapy: A novel adjunctive strategy in the management of an infected right atrial thrombus
An 81‐year‐old man presented with a large, infected right atrial thrombus that was refractory to anticoagulants and several courses of antibiotics. The risk of surgical removal of the thrombus, which was associated with a pacemaker electrode, was considered prohibitive. The patient was treated for 7 days with low‐dose (40 mg/day) tissue‐type plasminogen activator (t‐PA). Hemostatic monitoring during infusion revealed (1) aplasma t‐PA antigen that was approximately 5% of that achieved during short‐course t‐PA for acute myocardial infarction, (2) biochemical evidence of prolonged clot lysis, and (3) no significant depletion of fibrinogen or plas‐minogen. Nearly complete dissolution of the thrombus was observed. His bacteremia was eradicated by intravenous penicillin despite the presence of the pacemaker lead. This case highlights the benefits of combined antibiotic and thrombolytic therapy and documents for the first time the response of the human hemostatic system to prolonged t‐PA infusion and the plasma t‐PA levels attained when thrombolytic therapy is administered in this manner. Prolonged courses of fibrinolytic agents may be a good alternative to surgical intervention in selected patients with infected, right‐sided intracardiac thrombi.
- 1 June 2002
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 22 (6) , 934-939
Endogenous Vitronectin and Plasminogen Activator Inhibitor-1 Promote Neointima Formation in Murine Carotid Arteries
We examined the roles of vitronectin and plasminogen activator inhibitor-1 (PAI-1) in neointima development. Neointima formation after carotid artery ligation or chemical injury was significantly g...
- 1 June 2002
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 22 (6) , 934-939
Endogenous Vitronectin and Plasminogen Activator Inhibitor-1 Promote Neointima Formation in Murine Carotid Arteries
We examined the roles of vitronectin and plasminogen activator inhibitor-1 (PAI-1) in neointima development. Neointima formation after carotid artery ligation or chemical injury was significantly g...
- 26 June 2001
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (25) , 3105-3110
Plasminogen Activator Inhibitor Type 1 Enhances Neointima Formation After Oxidative Vascular Injury in Atherosclerosis-Prone Mice
Background —Plasminogen activator inhibitor type 1 (PAI-1) inhibits neointima formation after vascular injury. Hyperlipidemia modulates the expression of multiple genes, however, and the effects of PAI-1 on the arterial response to injury under hyperlipidemic conditions are unknown. The purpose of this study was to examine the impact of PAI-1 on intimal hyperplasia and other vascular changes that develop after arterial injury in apolipoprotein E–deficient (apoE −/− ) mice. Methods and Results —Ferric chloride injury of the midportion of the common carotid arteries of apoE −/− mice (n=22) induced formation of a neointima that contained smooth muscle cells, foam cells, neutral lipid, tissue factor, and von Willebrand factor. Interactions between vascular injury and apolipoprotein E deficiency were strongly synergistic; either stimulus alone was insufficient to induce significant neointima formation. Mean intima/media ratios were significantly greater ( P −/− , PAI-1 +/+ mice (5.6±1.8, n=12) than in apoE −/− , PAI-1 −/− mice (1.2±0.55, n=12), as were the percentages of bromodeoxyuridine-positive cells in the intima and media ( P −/− , PAI-1 +/+ mice than in apoE −/− , PAI-1 −/− mice. Conclusions —In atherosclerosis-prone mice, PAI-1 promotes neointima formation after oxidative vascular injury. The apparent hyperlipidemia-dependent effect of PAI-1 may be mediated by its capacity to inhibit the clearance of platelet-fibrin thrombi that can deliver growth factors to the blood vessel wall or be incorporated into developing vascular lesions. Alternatively, hyperlipidemia may alter the pattern of gene expression in the blood vessel wall to enhance potential effects of PAI-1 on antiproliferative processes, such as transforming growth factor-β activation and apoptosis.
- 26 June 2001
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (25) , 3105-3110
Plasminogen Activator Inhibitor Type 1 Enhances Neointima Formation After Oxidative Vascular Injury in Atherosclerosis-Prone Mice
Background —Plasminogen activator inhibitor type 1 (PAI-1) inhibits neointima formation after vascular injury. Hyperlipidemia modulates the expression of multiple genes, however, and the effects of PAI-1 on the arterial response to injury under hyperlipidemic conditions are unknown. The purpose of this study was to examine the impact of PAI-1 on intimal hyperplasia and other vascular changes that develop after arterial injury in apolipoprotein E–deficient (apoE −/− ) mice. Methods and Results —Ferric chloride injury of the midportion of the common carotid arteries of apoE −/− mice (n=22) induced formation of a neointima that contained smooth muscle cells, foam cells, neutral lipid, tissue factor, and von Willebrand factor. Interactions between vascular injury and apolipoprotein E deficiency were strongly synergistic; either stimulus alone was insufficient to induce significant neointima formation. Mean intima/media ratios were significantly greater ( P −/− , PAI-1 +/+ mice (5.6±1.8, n=12) than in apoE −/− , PAI-1 −/− mice (1.2±0.55, n=12), as were the percentages of bromodeoxyuridine-positive cells in the intima and media ( P −/− , PAI-1 +/+ mice than in apoE −/− , PAI-1 −/− mice. Conclusions —In atherosclerosis-prone mice, PAI-1 promotes neointima formation after oxidative vascular injury. The apparent hyperlipidemia-dependent effect of PAI-1 may be mediated by its capacity to inhibit the clearance of platelet-fibrin thrombi that can deliver growth factors to the blood vessel wall or be incorporated into developing vascular lesions. Alternatively, hyperlipidemia may alter the pattern of gene expression in the blood vessel wall to enhance potential effects of PAI-1 on antiproliferative processes, such as transforming growth factor-β activation and apoptosis.
- 15 June 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 99 (23) , 3050-3055
Plasminogen Activator Inhibitor-1 Is a Major Determinant of Arterial Thrombolysis Resistance
Background —Platelet-rich thrombi are resistant to lysis by tissue plasminogen activator (tPA). Plasminogen activator inhibitor-1 (PAI-1), a rapid inhibitor of tPA, may contribute to arterial thrombolysis resistance. However, few data are available regarding the effect of PAI-1 on arterial thrombolysis in animals. We used a murine carotid injury model to test the hypothesis that PAI-1 inhibits thrombolysis mediated by pharmacological concentrations of tPA. Methods and Results —Platelet-rich thrombi were induced in wild-type mice ( PAI-1 +/+; n=11) and PAI-1–deficient mice ( PAI-1 −/−; n=11) with ferric chloride. Baseline carotid blood flows and mean occlusion times did not differ between PAI-1 +/+ and PAI-1 −/− mice. Clot lysis was induced by infusion of heparin (200 U/kg bolus, 70 U · kg −1 · h −1 drip), human plasminogen (50 mg/kg), and tPA at 20 (n=10) or 100 (n=12) μg · kg −1 · min −1 . Mean plasma tPA antigens were 2.7 μg/mL (tPA infusion, 20 μg · kg −1 · min −1 ) and 5.5 μg/mL (tPA infusion, 100 μg · kg −1 · min −1 ), with no significant differences between PAI-1 +/+ mice and PAI-1 −/− mice. Reperfusion after tPA 20 μg · kg −1 · min −1 occurred in 1 of 5 PAI-1 +/+ mice versus 5 of 5 PAI-1 −/− mice ( P =0.0006). Reperfusion occurred in all mice that received tPA 100 μg · kg −1 · min −1 , but reperfusion times were significantly shorter in PAI-1 −/− mice (17.8±2.6 minutes, n=6) than in PAI-1 +/+ mice (35.7±5.1 minute, n=6; P =0.01). Histological analyses confirmed that carotid thrombi were platelet rich and that PAI-1 was distributed uniformly throughout thrombi from PAI-1 +/+ mice. Lysates of PAI-1 +/+ platelets inhibited human tPA, whereas PAI-1 −/− platelet lysates did not. Conclusions —PAI-1 is a major determinant of the resistance of platelet-rich arterial thrombi to lysis by pharmacological concentrations of tPA. Strategies to inhibit or resist PAI-1 may enhance thrombolysis.
- 15 June 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 99 (23) , 3050-3055
Plasminogen Activator Inhibitor-1 Is a Major Determinant of Arterial Thrombolysis Resistance
Background —Platelet-rich thrombi are resistant to lysis by tissue plasminogen activator (tPA). Plasminogen activator inhibitor-1 (PAI-1), a rapid inhibitor of tPA, may contribute to arterial thrombolysis resistance. However, few data are available regarding the effect of PAI-1 on arterial thrombolysis in animals. We used a murine carotid injury model to test the hypothesis that PAI-1 inhibits thrombolysis mediated by pharmacological concentrations of tPA. Methods and Results —Platelet-rich thrombi were induced in wild-type mice ( PAI-1 +/+; n=11) and PAI-1–deficient mice ( PAI-1 −/−; n=11) with ferric chloride. Baseline carotid blood flows and mean occlusion times did not differ between PAI-1 +/+ and PAI-1 −/− mice. Clot lysis was induced by infusion of heparin (200 U/kg bolus, 70 U · kg −1 · h −1 drip), human plasminogen (50 mg/kg), and tPA at 20 (n=10) or 100 (n=12) μg · kg −1 · min −1 . Mean plasma tPA antigens were 2.7 μg/mL (tPA infusion, 20 μg · kg −1 · min −1 ) and 5.5 μg/mL (tPA infusion, 100 μg · kg −1 · min −1 ), with no significant differences between PAI-1 +/+ mice and PAI-1 −/− mice. Reperfusion after tPA 20 μg · kg −1 · min −1 occurred in 1 of 5 PAI-1 +/+ mice versus 5 of 5 PAI-1 −/− mice ( P =0.0006). Reperfusion occurred in all mice that received tPA 100 μg · kg −1 · min −1 , but reperfusion times were significantly shorter in PAI-1 −/− mice (17.8±2.6 minutes, n=6) than in PAI-1 +/+ mice (35.7±5.1 minute, n=6; P =0.01). Histological analyses confirmed that carotid thrombi were platelet rich and that PAI-1 was distributed uniformly throughout thrombi from PAI-1 +/+ mice. Lysates of PAI-1 +/+ platelets inhibited human tPA, whereas PAI-1 −/− platelet lysates did not. Conclusions —PAI-1 is a major determinant of the resistance of platelet-rich arterial thrombi to lysis by pharmacological concentrations of tPA. Strategies to inhibit or resist PAI-1 may enhance thrombolysis.
- Open Access
- 15 March 1999
- Published by American Society of Hematology in Blood
- Vol. 93 (6) , 1825-1830
Vitronectin Inhibits the Thrombotic Response to Arterial Injury in Mice
Vitronectin (VN) binds to plasminogen activator inhibitor-1 (PAI-1) and integrins and may play an important role in the vascular response to injury by regulating fibrinolysis and cell migration. However, the role of VN in the earliest response to vascular injury, thrombosis, is not well characterized. The purpose of this study was to test the hypothesis that variation in vitronectin expression alters the thrombotic response to arterial injury in mice. Ferric chloride (FeCl3) injury was used to induce platelet-rich thrombi in mouse carotid arteries. Wild-type (VN +/+, n = 14) and VN-deficient (VN −/−, n = 15) mice, matched for age and gender, were studied. Time to occlusion after FeCl3 injury was determined by application of a Doppler flowprobe to the carotid artery. Occlusion times of VN −/− mice were significantly shorter than those of VN +/+ mice (6.0 ± 1.2 minutesv 17.8 ± 2.3 minutes, respectively, P < .001). Histologic analysis of injured arterial segments showed that thrombi from VN +/+ and VN −/− mice consisted of dense platelet aggregates. In vitro studies of murine VN +/+ andVN −/− platelets showed no significant differences in ADP-induced aggregation, but a trend towards increased thrombin-induced aggregation in VN −/− platelets. Purified, denatured VN inhibited thrombin-induced platelet aggregation, whereas native VN did not. Thrombin times of plasma from VN −/− mice (20.5 ± 2.1 seconds, n = 4) were significantly shorter than those ofVN +/+ mice (34.2 ± 6.7 seconds, n = 4, P < .01), and the addition of purified VN to VN −/− plasma prolonged the thrombin time into the normal range, suggesting that VN inhibits thrombin-fibrinogen interactions. PAI-1-deficient mice (n = 6) did not demonstrate significantly enhanced arterial thrombosis compared with wild-type mice (n = 6), excluding a potential indirect antithrombin function of VN mediated by interactions with PAI-1 as an explanation for the accelerated thrombosis observed in VN−/− mice. These results suggest that vitronectin plays a previously unappreciated antithrombotic role at sites of arterial injury and that this activity may be mediated, at least in part, by inhibiting platelet-platelet interactions and/or thrombin procoagulant activity.
- 15 March 1999
- Published by American Society of Hematology in Blood
- Vol. 93 (6) , 1825-1830
Open AccessVitronectin Inhibits the Thrombotic Response to Arterial Injury in Mice
Vitronectin (VN) binds to plasminogen activator inhibitor-1 (PAI-1) and integrins and may play an important role in the vascular response to injury by regulating fibrinolysis and cell migration. However, the role of VN in the earliest response to vascular injury, thrombosis, is not well characterized. The purpose of this study was to test the hypothesis that variation in vitronectin expression alters the thrombotic response to arterial injury in mice. Ferric chloride (FeCl3) injury was used to induce platelet-rich thrombi in mouse carotid arteries. Wild-type (VN +/+, n = 14) and VN-deficient (VN −/−, n = 15) mice, matched for age and gender, were studied. Time to occlusion after FeCl3 injury was determined by application of a Doppler flowprobe to the carotid artery. Occlusion times of VN −/− mice were significantly shorter than those of VN +/+ mice (6.0 ± 1.2 minutesv 17.8 ± 2.3 minutes, respectively, P < .001). Histologic analysis of injured arterial segments showed that thrombi from VN +/+ and VN −/− mice consisted of dense platelet aggregates. In vitro studies of murine VN +/+ andVN −/− platelets showed no significant differences in ADP-induced aggregation, but a trend towards increased thrombin-induced aggregation in VN −/− platelets. Purified, denatured VN inhibited thrombin-induced platelet aggregation, whereas native VN did not. Thrombin times of plasma from VN −/− mice (20.5 ± 2.1 seconds, n = 4) were significantly shorter than those ofVN +/+ mice (34.2 ± 6.7 seconds, n = 4, P < .01), and the addition of purified VN to VN −/− plasma prolonged the thrombin time into the normal range, suggesting that VN inhibits thrombin-fibrinogen interactions. PAI-1-deficient mice (n = 6) did not demonstrate significantly enhanced arterial thrombosis compared with wild-type mice (n = 6), excluding a potential indirect antithrombin function of VN mediated by interactions with PAI-1 as an explanation for the accelerated thrombosis observed in VN−/− mice. These results suggest that vitronectin plays a previously unappreciated antithrombotic role at sites of arterial injury and that this activity may be mediated, at least in part, by inhibiting platelet-platelet interactions and/or thrombin procoagulant activity.